Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Non-cash Items: 2015-2025

Historic Non-cash Items for Voyager Therapeutics (VYGR) over the last 10 years, with Sep 2025 value amounting to $3.1 million.

  • Voyager Therapeutics' Non-cash Items fell 16.21% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 16.21%. This contributed to the annual value of $4.8 million for FY2024, which is 26.53% up from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Non-cash Items is $3.1 million, which was up 1,174.09% from $247,000 recorded in Q2 2025.
  • Voyager Therapeutics' Non-cash Items' 5-year high stood at $17.9 million during Q1 2024, with a 5-year trough of $247,000 in Q2 2025.
  • In the last 3 years, Voyager Therapeutics' Non-cash Items had a median value of $3.8 million in 2023 and averaged $5.8 million.
  • In the last 5 years, Voyager Therapeutics' Non-cash Items soared by 470.49% in 2024 and then crashed by 97.39% in 2025.
  • Quarterly analysis of 5 years shows Voyager Therapeutics' Non-cash Items stood at $1.2 million in 2021, then soared by 423.18% to $6.1 million in 2022, then slumped by 37.27% to $3.8 million in 2023, then increased by 26.53% to $4.8 million in 2024, then decreased by 16.21% to $3.1 million in 2025.
  • Its Non-cash Items stands at $3.1 million for Q3 2025, versus $247,000 for Q2 2025 and $5.1 million for Q1 2025.